WO2004019923A1 - Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries - Google Patents

Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries Download PDF

Info

Publication number
WO2004019923A1
WO2004019923A1 PCT/EP2003/009746 EP0309746W WO2004019923A1 WO 2004019923 A1 WO2004019923 A1 WO 2004019923A1 EP 0309746 W EP0309746 W EP 0309746W WO 2004019923 A1 WO2004019923 A1 WO 2004019923A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
derivative
arteries
medicament
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/009746
Other languages
French (fr)
Inventor
Cees Vermeer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VITAK BV
Original Assignee
VITAK BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004019923(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/525,591 priority Critical patent/US20060166948A1/en
Priority to AU2003264150A priority patent/AU2003264150A1/en
Priority to DK03790959.5T priority patent/DK1556025T3/en
Priority to AT03790959T priority patent/ATE499094T1/en
Priority to EP03790959A priority patent/EP1556025B1/en
Application filed by VITAK BV filed Critical VITAK BV
Priority to SI200331997T priority patent/SI1556025T1/en
Priority to DE60336161T priority patent/DE60336161D1/en
Publication of WO2004019923A1 publication Critical patent/WO2004019923A1/en
Anticipated expiration legal-status Critical
Priority to US11/144,853 priority patent/US9364447B2/en
Priority to US15/151,970 priority patent/US12144785B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention concerns the use of vitamin K and derivatives thereof to prevent or treat a reduction in elasticity and distensibility of the vasculature, and thereby to lower blood pressure and prevent cardiovascular disease.
  • Vitamin K is an essential component of the diet. It was first identified as an element needed to prevent haemorrhaging by activating blood-clotting factors. Natural K-vitamers are menadione-derivatives differing from each other in the polyisoprenoid side chain attached to the 3-position of the ring structure. Vitamin K can be provided in the diet by dark green, leafy vegetables (K., or phylloquinone), and by fermented foods such as cheese and curd (K 2 or menaquinone). K 2 vitamins are also synthesized in the small intestine by resident symbiotic bacteria. Vitamin K is also needed for carboxylation of two bone matrix proteins necessary for normal bone metabolism.
  • arteriosclerosis is a disease of the arteries characterized by inflammation, macrophage invasion, foam cell formation, intima thickening, accretion of cholesterol, and formation of an atherosclerotic plaque.
  • the onset of atherosclerosis is invariably in the large arteries such aorta and coronary arteries. In more advanced stages one may see plaque rupture leading to sudden vascular occlusion, myocardial infarction and cerebrovascular accident (infarction of the brain).
  • vascular stiffening due to loss of elasticity of the arteries.
  • Vascular stiffening is associated with ageing, diabetes mellitus and renal dysfunction; it is the result of degradation of the elastic lamellae in the tunica media resulting in loss of elasticity.
  • the onset of vascular stiffening is generally seen in the smaller vessels, from extends to the larger arteries. This will lead to increased blood pressure, vascular widening, and in later stages to rupture of (mainly the small) arteries and capillaries.
  • the present patent application relates to the effect of vitamin K on vascular stiffening. Studies have shown that also on a molecular level age-related stiffening of the arteries can be distinguished from arteriosclerotic/atherosclerotic calcification.
  • age-related stiffening is a process which originates in the tunica media, and is not associated with inflammation. It is believed that age-related stiffening occurs as a result of deposition of minerals around the elastic fibres of the tunica media, followed by degradation of the elastin structure. After deterioration of the elastin, the elastic properties of the artery depend on collagen, which is much less flexible.
  • vitamin K is a useful therapeutic measure to prevent the development of cardiovascular disease conditions including hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke, Monckeberg's sclerosis and coronary heart disease.
  • the invention provides use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing age-related stiffening of arteries.
  • the invention provides use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing an age-related decrease in compliance and/or distensibility of arteries and/or an age-related increase in pulse pressure.
  • the invention provides use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing any of: hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke, Monckeberg's sclerosis, and coronary heart disease.
  • the invention provides a composition for promoting healthy arteries, comprising vitamin K or a derivative thereof, and optionally vitamin D or a derivative thereof, and one or more additional components selected from: polyphenols, vitamin C, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty acids, carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B12.
  • additional components selected from: polyphenols, vitamin C, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty acids, carnitine, taurine,
  • composition for promoting healthy arteries which comprises: 0.5-1.5mg vitamin K; 5-1 O ⁇ g vitamin D; 450- 550mg Calcium; 7-12 mg Zinc; and 100-200mg Magnesium.
  • kits comprising Vitamin K or a derivative thereof, and optionally vitamin D or a derivative thereof and a medicament, for simultaneous, separate or sequential administration, wherein said medicament is selected from the group consisting of: anticoagulants, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents, beta- blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, anti- arrhythmics, and calcium antagonists.
  • Figure 1 shows how the Distensibility Coefficient (DC) varies over a 3 year study period when placebo, Vitamin D (MD) and Vitamins K plus D (MDK) are administered to a group of postmenopausal women.
  • DC Distensibility Coefficient
  • Figure 2 shows how the Compliance Coefficient (CC) varies over a 3 year study period when placebo, Vitamin D (MD) and Vitamins K plus D (MDK) are administered to a group of postmenopausal women.
  • CC Compliance Coefficient
  • the black bar represents the baseline measurement (100%), and the shaded bars are the % change relative to baseline after 3 years.
  • This invention provides the first form of directed therapy for reducing age-related arterial stiffening (as distinct from stiffening due to atherosclerosis).
  • Arterial elastic properties (compliance and distensibility) deteriorate with age.
  • the severity of this downward trend was found to be significantly reduced in a group of menopausal women who regularly consumed a supplement of vitamin K (plus Vitamin D) over the course of 3 years. These women were selected for the study on the basis of criteria which included a lack of evidence of atherosclerotic disease and low risk factors for the disease.
  • vitamin K and derivatives refers to one or more compounds of Formula 1', and/or their pharmaceutically or nutritionally acceptable salts,
  • R may be any covalently linked organic group including polyisoprenoid residues, esters, ethers, thiol adducts, etc.
  • n is an integer from 1 to 12; and in which the broken lines indicate the optional presence of a double bond.
  • Sources of vitamin K which can be used according to the present invention include the following: phylloquinone from natural sources such as vegetable extracts, fats and oils, synthetic phylloquinone, synthetic vitamin K 3 (menadione), different forms of vitamin K 2 : synthetic MK-4, MK-5, MK-6, MK-7, MK-8, MK-9, MK-10, MK-11 , MK-12 and MK-13, natto (food prepared from fermented soy-bean, rich in MK-7), and other fermented foods or dairy products.
  • the dose of vitamin K useful in performing the invention is not restricted but varies depending on, for example, the age of the subject and the degree of risk of developing arterial stiffening.
  • Current Al values or Adequate Intakes are 120 ⁇ g for men and 90 ⁇ g for women.
  • Benefits may be derived by selecting dosages higher than the Al values, particularly in population groups where vitamin K deficiencies are common, for instance among postmenopausal women.
  • suitable dosages may lie in the range 10 to 1000 ⁇ g, more preferably 50 to 500 ⁇ g, and most preferably 100 to 200 ⁇ g vitamin K/day.
  • daily dosage may vary between 0.5 to 50 ⁇ g/kg body weight/day, preferably 0.75 to 25 ⁇ g/kg body weight/day, more preferred 1 to 15 ⁇ g/kg body weight/day.
  • Vitamin D is included together with vitamin K in the composition used in the clinical study, and may play a role in supporting the function of vitamin K in preventing arterial stiffening.
  • Any form of natural or synthetic vitamin D may be employed, including vitamin D.,, vitamin D 2 (calciferol), vitamin D 3 (cholecalciferol) and vitamin D analogues (e.g. alfacalcidol, dihydrotachysterol, calcitriol).
  • Natural sources of vitamin D include saltwater fish, organ meats, fish-liver oils and egg yolk. Suitable dosages of vitamin D are 2 to 50 ⁇ g/day, preferably 5 to 20 ⁇ g/day, and most preferably about 7 to 10 ⁇ g/day.
  • Vitamin K is conventionally provided in the form of tablets or capsules, i.e. in a pharmaceutical or dietary supplement format.
  • the vitamin K may be compounded with pharmaceutically acceptable carriers, excipients or diluents in the forms of pills, tablets (coated or uncoated), hard or soft capsules, dragees, lozenges, oral solutions, suspensions and dispersions, syrups or sterile parenteral preparations.
  • Suitable excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate; granulating and disintegrating agents such as cornstarch or alginic acid; binding agents such as starch gelatin or acacia; effervescents; and lubricating agents such as magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate
  • granulating and disintegrating agents such as cornstarch or alginic acid
  • binding agents such as starch gelatin or acacia
  • effervescents effervescents
  • lubricating agents such as magnesium stearate, stearic acid or talc.
  • Vitamin K (optionally together with vitamin D) in a fortified food or beverage product.
  • Preferred nutritional product formats include: juice drinks, dairy drinks, powdered drinks, sports drinks, mineral water, soy beverages, hot chocolate, malt drinks, biscuits, bread, crackers, confectioneries, chocolate, chewing-gum, margarines, spreads, yoghurts, breakfast cereals, snack bars, meal replacements, protein powders, desserts, and medical nutrition tube feeds and nutritional supplements.
  • compositions of the invention may be included in the compositions of the invention, including any of those selected from preservatives, chelating agents, effervescing agents, natural or artificial sweeteners, flavoring agents, coloring agents, taste masking agents, acidulants, emulsifiers, thickening agents, suspending agents, dispersing or wetting agents, antioxidants, and the like.
  • vitamin K and optionally vitamin D
  • other healthy or pharmaceutically active components in a single composition, or in the form of a kit for simultaneous, sequential or separate administration.
  • vitamin K could be provided in conjunction with medicaments selected from anticoagulants such as aspirin or COX-2 inhibitors, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents including statins, bile acid sequestrants, nicotinic acid derivatives, and fibrates, beta-blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics, and calcium antagonists.
  • anticoagulants such as aspirin or COX-2 inhibitors, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents including statins, bile acid sequestrants, nicotinic acid derivatives, and fibrates, beta-blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics, and calcium antagonists.
  • anticoagulants such aspirin or COX-2 inhibitors, antithrombotics
  • bioactive substances for co-administration include: polyphenols, vitamin C, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty acids, carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B12.
  • vitamin K is effective at limiting age-related stiffness throughout the network of arteries in the body, its therapeutic effect on the body is probably most significant with respect to its influence on the larger elastic arteries of the body, especially the common carotid arteries supplying blood to the neck and head, the aorta, and the renal arteries.
  • vitamin K also has the effects of counteracting the sequelae of arterial stiffening, .. namely hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease.
  • Elevated blood pressure or “hypertension” as used herein refers to a blood pressure persistently exceeding 140/90 mmHg (systolic/diastolic).
  • Inclusion criteria were: apparently healthy women, Caucasian, between 50 and 60 years old, and at least 2 years postmenopausal. Exclusion criteria were: use of oral anticoagulants, corticosteroids, hormone replacement therapy, vitamin concentrates or food supplements, and high alcohol consumption (> 6 glasses/day). In total 181 women met the criteria for participation and were randomized into the study. Information on cardiovascular risk factors, current health status, medical history, drug use and smoking behaviour was collected before the start of the study. Within this trial participants underwent clinical examinations at 0, 3, 12, 18, 24 and 36 months. The vascular examinations took place at baseline and at the end of the study after 3 years. All participants gave written informed consent and the trial was approved by the Maastricht University Hospital Medical Ethics Committee.
  • the three different types of supplements were similar in appearance and taste, and participants were allowed to choose between a supplement in the form of a tasteless powder (to be mixed with water before intake) or in the form of chocolate-coated tablets with a crunchy malt core. Participants were instructed to take one sachet with powder or three tablets per day during evening hours, preferably after the meal. Also, they were advised to maintain their usual diets and to avoid taking supplements containing either calcium, vitamin D, or vitamin K for two months before and throughout the study. Novartis Consumer Health SA (Nyon, Switzerland) prepared and provided all supplements.
  • the right common carotid artery of each patient was investigated. The same investigator performed all examinations at the start and the end of the study and for each participant several repeated measurements (5-7) are made during one session. Reproducibility was evaluated for assessment of common carotid artery distension and diameter.
  • the primary outcome measures for the purposes of this study were the vessel wall characteristics of the common carotid artery measured with ultrasound (ATL Mark V).
  • the ultrasonic vessel wall tracking system (WTS) to determine arterial wall properties has been described in detail before (Hoeks AP et al., Ultrasound Med Biol 1990; 16:121-8, and Kool MJF et al., Cardiovascular Research 1994;28:610-614).
  • This ultrasound system provides estimates of the arterial end-diastolic diameter (d) and the change in diameter from diastole to systole ( ⁇ d) normalized for the end-diastolic diameter ( ⁇ d/d) for each captured heart beat.
  • ⁇ p Pulse pressure
  • DC vascular distensibility
  • CC compliance
  • IMT intima-media thickness
  • a paired t-test was used to evaluate the change in the vessel wall characteristics over the three years within each group. We considered a level of p ⁇ 0.05 to be statistically significant. For every participant, the percentage change from baseline in all parameters was calculated and the mean change from baseline was calculated per group. Primary outcome analysis consisted of comparison of the change in DC, CC, PP and IMT between the MD-group and placebo and between the MDK-group and placebo. Linear regression analysis was used with the change in vascular parameters relative to baseline as dependent variable and the treatment groups and several covariates as explanatory variables. Baseline values of age, BMI, smoking (yes or no), heart rate and mean arterial pressure were chosen as covariates, because their influence on the change in vascular properties or response to the supplementation could not be excluded.
  • Table 1 details the baseline measurements of each study group.
  • Table 2 summarizes per group the differences between the mean values at baseline and at the end of the study for all vascular parameters with their paired-levels of significance.
  • the DC and CC in the placebo group decreased significantly (by 10% and 6%, respectively).
  • the PP on the other hand, increased by 7%, but the increase did not reach the level of significance.
  • DC decreased significantly (by 7%)
  • CC decreased by 4%, while the PP increased by 6%; however these latter two changes did not reach the level of significance.
  • the DC and CC remained approximately constant over the three year period, the CC even showing a tendency to increase (+3%). The PP remained unchanged throughout the entire study period.
  • Figures 1 and 2 illustrate the percentage change in DC and CC respectively of the three groups.
  • the changes in the placebo- relative to the MDK-group remained statistically significant and were: 8.8% decrease of DC (95% Cl: 1.9 to 21.4), 8.6% decrease of CC (95% Cl: 1.8 to 20.3), and 6.3% increase of PP (95%) Cl: -17.1 to -0.7).
  • the changes in the placebo- and the MD-group 2.5% decrease of DC (95% Cl: -14.8 to 6.3), 2.2% decrease of CC (95% Cl: -13.8 to 6.3), and 0.11% increase of PP (95% Cl: -5.6 to 12.1).
  • the MD group who received a vitamin D supplement, failed to show any improvement in measures of vascular wall aging relative to the placebo group. It can be concluded that provision of vitamin D alone is not capable of delivering cardiovascular benefits to postmenopausal women fulfilling the criteria applied in the present study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Vitamin K is effective in counteracting the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke.

Description

COMPOSITIONS COMPRISING VITAMIN K FOR TREATING OR PREVENTING AGE-RELATED STIFFENING OF ARTERIES
Field of the invention The present invention concerns the use of vitamin K and derivatives thereof to prevent or treat a reduction in elasticity and distensibility of the vasculature, and thereby to lower blood pressure and prevent cardiovascular disease.
Background The process of aging is associated with irreversible physiological changes to the circulatory system, leading to an increased risk of blood pressure disorders, Coronary Heart Disease (CHD), and stroke. For women, this risk rises dramatically after the onset of menopause. These conditions have a significant impact on quality of life for the middle- aged and elderly and account for a large proportion of deaths and chronic illnesses in modern societies.
Patients suffering from cardiovascular disorders are frequently prescribed anticoagulants, antihypertensives, cholesterol-lowering medications, and the like. These medications usually present harmful side-effects or health risks, and moreover, the chronic effects of taking such medication regularly over the course of years or decades are not well studied. As life expectancies increase, it would be desirable to find long-term, safe and reliable natural therapies to prevent, treat or even reverse the consequences of aging on the vasculature.
Changes in mechanical properties of the main arteries have major implications for the development of vascular disease. Arteries, especially the larger elastic arteries such as the common carotid artery, become stiffer with age. Peak elasticities are achieved at about age 14-15, after which they deteriorate gradually. Measures of large artery stiffening include compliance and distensibility. Compliance reflects the buffering capacity of the vascular vessel wall, and distensibility refers to the intrinsic vascular wall elasticity. In cross-sectional studies it has been shown that the distensibility and compliance of the elastic common carotid artery decrease linearly with age. The increase in arterial stiffness with increasing age is suggested to occur more rapidly in women aged between 45 and 60 years than in men of the same age group due to the lack of oestrogen after menopause.
Reductions in complicance and distensibility result in an impairment of the arterial system to cushion pulsatile pressure. Arterial stiffening results in a higher pulse wave velocity and earlier wave reflections. This increases systolic and pulse pressure and consequently cardiac workload. To compensate, the arterial diameter increases with age. Over time, arterial stiffening can contribute to the development of inter alia left ventricular hypertrophy, congestive heart failure and coronary heart disease.
It has long been recognized that vitamin K is an essential component of the diet. It was first identified as an element needed to prevent haemorrhaging by activating blood-clotting factors. Natural K-vitamers are menadione-derivatives differing from each other in the polyisoprenoid side chain attached to the 3-position of the ring structure. Vitamin K can be provided in the diet by dark green, leafy vegetables (K., or phylloquinone), and by fermented foods such as cheese and curd (K2 or menaquinone). K2 vitamins are also synthesized in the small intestine by resident symbiotic bacteria. Vitamin K is also needed for carboxylation of two bone matrix proteins necessary for normal bone metabolism.
In EP-A-0 679 394 and likewise in Jpn. J. Pharmacol. (1997) 75:135-143 it is disclosed that a high dietary intake of vitamin K and related molecules can reduce arterial calcification, from which it is concluded that arteriosclerosis can be treated using vitamin K. Arteriosclerosis is a disease of the arteries characterized by inflammation, macrophage invasion, foam cell formation, intima thickening, accretion of cholesterol, and formation of an atherosclerotic plaque. The onset of atherosclerosis is invariably in the large arteries such aorta and coronary arteries. In more advanced stages one may see plaque rupture leading to sudden vascular occlusion, myocardial infarction and cerebrovascular accident (infarction of the brain).
A completely different process is that of vascular stiffening due to loss of elasticity of the arteries. Vascular stiffening is associated with ageing, diabetes mellitus and renal dysfunction; it is the result of degradation of the elastic lamellae in the tunica media resulting in loss of elasticity. The onset of vascular stiffening is generally seen in the smaller vessels, from extends to the larger arteries. This will lead to increased blood pressure, vascular widening, and in later stages to rupture of (mainly the small) arteries and capillaries. The present patent application relates to the effect of vitamin K on vascular stiffening. Studies have shown that also on a molecular level age-related stiffening of the arteries can be distinguished from arteriosclerotic/atherosclerotic calcification. Whereas atherosclerosis is invariably associated with inflammation and starts with destruction of the endothelial cell layer at the luminal side of the tunica intima, age- related stiffening is a process which originates in the tunica media, and is not associated with inflammation. It is believed that age-related stiffening occurs as a result of deposition of minerals around the elastic fibres of the tunica media, followed by degradation of the elastin structure. After deterioration of the elastin, the elastic properties of the artery depend on collagen, which is much less flexible.
For the first time, it has now been shown that arterial compliance and distensibility can be improved long-term by administering vitamin K, relative to subjects receiving no nutritional supplementation (placebo). Thus, administration of vitamin K is a useful therapeutic measure to prevent the development of cardiovascular disease conditions including hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke, Monckeberg's sclerosis and coronary heart disease.
Summary of the Invention
In a first aspect, the invention provides use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing age-related stiffening of arteries. In a second aspect, the invention provides use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing an age-related decrease in compliance and/or distensibility of arteries and/or an age-related increase in pulse pressure. In another aspect, the invention provides use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing any of: hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke, Monckeberg's sclerosis, and coronary heart disease. In a further aspect, the invention provides a composition for promoting healthy arteries, comprising vitamin K or a derivative thereof, and optionally vitamin D or a derivative thereof, and one or more additional components selected from: polyphenols, vitamin C, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty acids, carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B12.
In another aspect of the invention there is provided a composition for promoting healthy arteries which comprises: 0.5-1.5mg vitamin K; 5-1 Oμg vitamin D; 450- 550mg Calcium; 7-12 mg Zinc; and 100-200mg Magnesium. In yet another aspect of the invention there is provided a kit comprising Vitamin K or a derivative thereof, and optionally vitamin D or a derivative thereof and a medicament, for simultaneous, separate or sequential administration, wherein said medicament is selected from the group consisting of: anticoagulants, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents, beta- blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, anti- arrhythmics, and calcium antagonists.
Description of the Figures Figure 1 shows how the Distensibility Coefficient (DC) varies over a 3 year study period when placebo, Vitamin D (MD) and Vitamins K plus D (MDK) are administered to a group of postmenopausal women.
Figure 2 shows how the Compliance Coefficient (CC) varies over a 3 year study period when placebo, Vitamin D (MD) and Vitamins K plus D (MDK) are administered to a group of postmenopausal women.
In each case the black bar represents the baseline measurement (100%), and the shaded bars are the % change relative to baseline after 3 years.
Detailed Description of the Invention This invention provides the first form of directed therapy for reducing age- related arterial stiffening (as distinct from stiffening due to atherosclerosis). Arterial elastic properties (compliance and distensibility) deteriorate with age. However, the severity of this downward trend was found to be significantly reduced in a group of menopausal women who regularly consumed a supplement of vitamin K (plus Vitamin D) over the course of 3 years. These women were selected for the study on the basis of criteria which included a lack of evidence of atherosclerotic disease and low risk factors for the disease.
Preferably vitamin K and derivatives refers to one or more compounds of Formula 1', and/or their pharmaceutically or nutritionally acceptable salts,
Figure imgf000005_0001
Formula V where R may be any covalently linked organic group including polyisoprenoid residues, esters, ethers, thiol adducts, etc.
and especially the compounds thereof of Formula 2:
Figure imgf000006_0001
Formula 2
in which n is an integer from 1 to 12; and in which the broken lines indicate the optional presence of a double bond.
Vitamin K and derivatives thereof, as used herein, refers in particular to phylloquinone (also known as vitamin K.,), dihydrophylloquinone; menaquinone-4 (MK-4) and the long chain menaquinones. It is generally accepted that the naphthoquinone is the functional group, so that the mechanism of action is similar for all K vitamins. Differences may be expected, however, with respect to intestinal absorption, transport, tissue distribution, and bioavailability. For use in the present invention, phylloquinone and MK-4 are preferred, and phylloquinone is particularly preferred.
Sources of vitamin K which can be used according to the present invention include the following: phylloquinone from natural sources such as vegetable extracts, fats and oils, synthetic phylloquinone, synthetic vitamin K3 (menadione), different forms of vitamin K2: synthetic MK-4, MK-5, MK-6, MK-7, MK-8, MK-9, MK-10, MK-11 , MK-12 and MK-13, natto (food prepared from fermented soy-bean, rich in MK-7), and other fermented foods or dairy products.
The dose of vitamin K useful in performing the invention is not restricted but varies depending on, for example, the age of the subject and the degree of risk of developing arterial stiffening. Current Al values or Adequate Intakes (as determined by the Institute of Medicine) are 120 μg for men and 90 μg for women. Benefits may be derived by selecting dosages higher than the Al values, particularly in population groups where vitamin K deficiencies are common, for instance among postmenopausal women. For example, suitable dosages may lie in the range 10 to 1000 μg, more preferably 50 to 500 μg, and most preferably 100 to 200 μg vitamin K/day. Where national legislation permits, it may be advisable to provide dosage ranges as high as from 1 to 200mg/day, preferably from 5 to 150 mg/day, and more preferably from 10 to 100 mg/day. No upper limit (UL) has been defined for vitamin K, since it is not known to have any adverse effects on the body.
In terms of body weight, daily dosage may vary between 0.5 to 50 μg/kg body weight/day, preferably 0.75 to 25 μg/kg body weight/day, more preferred 1 to 15 μg/kg body weight/day.
Vitamin D is included together with vitamin K in the composition used in the clinical study, and may play a role in supporting the function of vitamin K in preventing arterial stiffening. Any form of natural or synthetic vitamin D may be employed, including vitamin D.,, vitamin D2 (calciferol), vitamin D3 (cholecalciferol) and vitamin D analogues (e.g. alfacalcidol, dihydrotachysterol, calcitriol). Natural sources of vitamin D include saltwater fish, organ meats, fish-liver oils and egg yolk. Suitable dosages of vitamin D are 2 to 50 μg/day, preferably 5 to 20 μg/day, and most preferably about 7 to 10 μg/day.
In the clinical study described in the Examples arterial wall property measurements were taken at t=0 and t=3 years. This is good support for concluding that ingestion of vitamin K over long periods is an effective way of limiting an increase in arterial stiffness. The preferred treatment period is a minimum of 6 months, more preferably at least 18 months, and ideally at least 36 months. In fact, as there are no adverse side-effects associated with dietary vitamin K supplementation, it should be regarded as an essential component of a healthy lifestyle over the course of a lifetime, and especially throughout middle age and old age.
The preferred route of administration of vitamin K is enterally, especially orally, but the parenteral or topical routes are viable alternatives. Vitamin K is conventionally provided in the form of tablets or capsules, i.e. in a pharmaceutical or dietary supplement format. For pharmaceutical preparations or dietary supplements the vitamin K may be compounded with pharmaceutically acceptable carriers, excipients or diluents in the forms of pills, tablets (coated or uncoated), hard or soft capsules, dragees, lozenges, oral solutions, suspensions and dispersions, syrups or sterile parenteral preparations. Suitable excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate; granulating and disintegrating agents such as cornstarch or alginic acid; binding agents such as starch gelatin or acacia; effervescents; and lubricating agents such as magnesium stearate, stearic acid or talc.
It is also possible to deliver Vitamin K (optionally together with vitamin D) in a fortified food or beverage product. Preferred nutritional product formats include: juice drinks, dairy drinks, powdered drinks, sports drinks, mineral water, soy beverages, hot chocolate, malt drinks, biscuits, bread, crackers, confectioneries, chocolate, chewing-gum, margarines, spreads, yoghurts, breakfast cereals, snack bars, meal replacements, protein powders, desserts, and medical nutrition tube feeds and nutritional supplements.
Conventional additives may be included in the compositions of the invention, including any of those selected from preservatives, chelating agents, effervescing agents, natural or artificial sweeteners, flavoring agents, coloring agents, taste masking agents, acidulants, emulsifiers, thickening agents, suspending agents, dispersing or wetting agents, antioxidants, and the like.
As consumers who are at risk from stiffening arteries are also inclined to develop other ageing-related disorders, it may be of benefit to combine vitamin K (and optionally vitamin D) with other healthy or pharmaceutically active components in a single composition, or in the form of a kit for simultaneous, sequential or separate administration. For instance, it is envisaged that vitamin K could be provided in conjunction with medicaments selected from anticoagulants such as aspirin or COX-2 inhibitors, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents including statins, bile acid sequestrants, nicotinic acid derivatives, and fibrates, beta-blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics, and calcium antagonists. Other bioactive substances for co-administration include: polyphenols, vitamin C, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty acids, carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B12.
Anyone perceived to be at risk from cardiovascular disorders or already suffering from conditions such as angina pectoris, hypertension, a history of stroke, and other cerebrovascular disorders can benefit from ingesting vitamin K in order to counteract age-related stiffening of the arteries. Particular target population groups are: postmenopausal women, diabetics, obese individuals, smokers, alcoholics, sedentary and inactive people, the elderly, hemodialysis patients, men over 40 years of age, people suffering from chronic stress, and those consuming an unhealthy diet prone to causing cardiovascular diseases.
Although it is believed that vitamin K is effective at limiting age-related stiffness throughout the network of arteries in the body, its therapeutic effect on the body is probably most significant with respect to its influence on the larger elastic arteries of the body, especially the common carotid arteries supplying blood to the neck and head, the aorta, and the renal arteries. By reducing arterial stiffening, vitamin K also has the effects of counteracting the sequelae of arterial stiffening, .. namely hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease.
"Elevated blood pressure" or "hypertension" as used herein refers to a blood pressure persistently exceeding 140/90 mmHg (systolic/diastolic).
Examples
Clinical Study to compare effects of supplementation of Vitamin D and Vitamin D + Vitamin K on a group of healthy postmenopausal women.
Subjects
The participants were enrolled in a 3-year double-blind placebo-controlled clinical trial in which the effects of minerals, vitamin D- and vitamin K-containing supplements were investigated on bone mineral density and vessel wall characteristics. Inclusion criteria were: apparently healthy women, Caucasian, between 50 and 60 years old, and at least 2 years postmenopausal. Exclusion criteria were: use of oral anticoagulants, corticosteroids, hormone replacement therapy, vitamin concentrates or food supplements, and high alcohol consumption (> 6 glasses/day). In total 181 women met the criteria for participation and were randomized into the study. Information on cardiovascular risk factors, current health status, medical history, drug use and smoking behaviour was collected before the start of the study. Within this trial participants underwent clinical examinations at 0, 3, 12, 18, 24 and 36 months. The vascular examinations took place at baseline and at the end of the study after 3 years. All participants gave written informed consent and the trial was approved by the Maastricht University Hospital Medical Ethics Committee.
Study Design
The subjects were randomized into three groups. In the first group (n=60) participants received a placebo (maltodextrin), in the second group (n=58) participants received a supplement containing 500 mg calcium (natural calcium complex derived from milk), 10mg zinc, 150 mg magnesium and 8 μg vitamin D3 (minerals + vitamin D = MD- group), and in the third group (n=63) participants received a supplement containing the same constituents as the MD group but with an additional 1mg of vitamin K^ (minerals + vitamins D+K = MDK-group). The three different types of supplements were similar in appearance and taste, and participants were allowed to choose between a supplement in the form of a tasteless powder (to be mixed with water before intake) or in the form of chocolate-coated tablets with a crunchy malt core. Participants were instructed to take one sachet with powder or three tablets per day during evening hours, preferably after the meal. Also, they were advised to maintain their usual diets and to avoid taking supplements containing either calcium, vitamin D, or vitamin K for two months before and throughout the study. Novartis Consumer Health SA (Nyon, Switzerland) prepared and provided all supplements.
The right common carotid artery of each patient was investigated. The same investigator performed all examinations at the start and the end of the study and for each participant several repeated measurements (5-7) are made during one session. Reproducibility was evaluated for assessment of common carotid artery distension and diameter.
Before the vascular examination, height and weight were measured with standardized equipment to estimate the body mass index (weight/height2).
Measurements
The primary outcome measures for the purposes of this study were the vessel wall characteristics of the common carotid artery measured with ultrasound (ATL Mark V). The ultrasonic vessel wall tracking system (WTS) to determine arterial wall properties has been described in detail before (Hoeks AP et al., Ultrasound Med Biol 1990; 16:121-8, and Kool MJF et al., Cardiovascular Research 1994;28:610-614). This ultrasound system provides estimates of the arterial end-diastolic diameter (d) and the change in diameter from diastole to systole (Δd) normalized for the end-diastolic diameter (Δd/d) for each captured heart beat. In parallel with diameter change measurement, arterial blood pressure was recorded at the level of the brachial artery by means of a semiautomated oscillometric device (DINAMAP). Pulse pressure (Δp), defined as systolic minus diastolic blood pressure, was determined by averaging the three measurements nearest to the distension measurements. From d, Δd and Δp, vascular distensibility (DC) and compliance (CC) were calculated according to the following equations:
DC = (2dΔd + Δd2)/(d2/Δp) (Distensibility Coefficient) CC = π(2dΔd + Δd2)/4Δp (Compliance Coefficient)
The intima-media thickness (IMT) of the posterior wall was measured simultaneously at the same location (2-3 cm proximal to the bifurcation) of the common carotid artery where the diameter and diameter changes were measured. At the end of the session, recorded IMT-files are processed employing the wall thickness program. The threshold for the derivative was maintained at 0.025. Each heart-beat within a recording resulted in an estimate of wall thickness; the median of the estimates per recording was used for further evaluation.
Statistical Analysis
Statistical analysis was performed using the Statistical Package SPSS (SPSS Corp, Chicago, IL). Results are presented as means + standard deviation (SD), unless indicated otherwise. Only participants who had completed the study were included in the analysis. Furthermore, participants who during the study had started to use medications which are known to have a direct effect on the vessel wall, were excluded from analysis. Also, participants with atherosclerotic plaques in the common carotid artery and a high variability in the results (arterial translation of > 2 mm and beat-to-beat variation in distension of > 20%) were excluded.
A paired t-test was used to evaluate the change in the vessel wall characteristics over the three years within each group. We considered a level of p<0.05 to be statistically significant. For every participant, the percentage change from baseline in all parameters was calculated and the mean change from baseline was calculated per group. Primary outcome analysis consisted of comparison of the change in DC, CC, PP and IMT between the MD-group and placebo and between the MDK-group and placebo. Linear regression analysis was used with the change in vascular parameters relative to baseline as dependent variable and the treatment groups and several covariates as explanatory variables. Baseline values of age, BMI, smoking (yes or no), heart rate and mean arterial pressure were chosen as covariates, because their influence on the change in vascular properties or response to the supplementation could not be excluded.
Vascular parameters of elasticity Table 1 details the baseline measurements of each study group. Table 2 summarizes per group the differences between the mean values at baseline and at the end of the study for all vascular parameters with their paired-levels of significance. As was to be expected, the DC and CC in the placebo group decreased significantly (by 10% and 6%, respectively). The PP, on the other hand, increased by 7%, but the increase did not reach the level of significance. In the MD-group, DC decreased significantly (by 7%) and CC decreased by 4%, while the PP increased by 6%; however these latter two changes did not reach the level of significance. In the MDK-group, however, the DC and CC remained approximately constant over the three year period, the CC even showing a tendency to increase (+3%). The PP remained unchanged throughout the entire study period.
Figures 1 and 2 (see also Table 3 and Table 3a) illustrate the percentage change in DC and CC respectively of the three groups. After adjustment for baseline heart rate, mean arterial pressure, age, weight and smoking, the changes in the placebo- relative to the MDK-group remained statistically significant and were: 8.8% decrease of DC (95% Cl: 1.9 to 21.4), 8.6% decrease of CC (95% Cl: 1.8 to 20.3), and 6.3% increase of PP (95%) Cl: -17.1 to -0.7). In the same analysis no differences were found between the changes in the placebo- and the MD-group: 2.5% decrease of DC (95% Cl: -14.8 to 6.3), 2.2% decrease of CC (95% Cl: -13.8 to 6.3), and 0.11% increase of PP (95% Cl: -5.6 to 12.1).
Discussion of Results
The deleterious effects on the arteries of aging over a period of 3 years are clearly evident from the control (placebo) group, and underline how rapidly the vasculature can go into decline. The medical practitioner, being aware of the link between a decrease in elasticity of the arteries and diverse cardiovascular conditions, would recognise from these data that there is an urgent need to find a treatment method capable of combating the rapid decline in arterial elasticity, particularly in postmenopausal women.
The MD group, who received a vitamin D supplement, failed to show any improvement in measures of vascular wall aging relative to the placebo group. It can be concluded that provision of vitamin D alone is not capable of delivering cardiovascular benefits to postmenopausal women fulfilling the criteria applied in the present study.
In stark contrast to the placebo and MD groups, the MDK group showed significant relative improvements in distensibility, compliance and pulse pressure over the 3 year period of the study. These results demonstrate that regular consumption of vitamin K, or of the combination of vitamin K and vitamin D, can slow and maybe even reverse the process of stiffening of the arteries. As a consequence of slowing down the process of arterial stiffening, vitamin K supplementation inevitably impacts on the incidence of cardiovascular disorders linked to arterial stiffening, including those related to increased strain on the heart and reduced responsiveness of the circulatory system to changes in demand. Table 1 Baseline characteristics (mean ± standard deviation) in the three treatment groups
Figure imgf000013_0001
* significant different from placebo (p<0.05)
** significant different from placebo and MDK-group (p<0.05)
Table 2: Change in vessel wall characteristics (mean ± SD) in study population after 3 years
Figure imgf000014_0001
Table 3
Mean % change from baseline in vessel wall characteristics.
(for each subject the % change from baseline is calculated for each variable and then the mean of these individual changes is calculated per group)
Figure imgf000015_0001
*significant difference with placebo after adjustment for age, weight, smoking, mean arterial pressure and heart rate (linear regression analysis table 3a)
Table 3a
Multivariate regression analysis of the effects of the MDK-group and the MD-group compared to placebo on the change in vessel wall characteristics after three years with the following covariables: baseline age, weight, smoking, heart rate and mean arterial pressure.
Figure imgf000016_0001

Claims

Claims
1. Use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing age-related stiffening of arteries.
2. Use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing an ageing-related decrease in compliance and/or distensibility of arteries and/or an ageing-related increase in pulse pressure.
3. Use of a composition according to claim 1 where in said artery stiffening results from calcification of the tunica media.
4. Use of a composition comprising vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in the manufacture of a medicament or nutritional formulation for treating or preventing any of: hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke, Monckeberg's sclerosis and coronary heart disease.
5. Use according to any of claims 1 to 4, wherein said vitamin K is vitamin K, (phylloquinone) or Vitamin K2 (menaquinone).
6. Use according to claim 5 wherein said vitamin K is vitamin K, (phylloquinone).
7. Use according to any of claims 1 to 6 wherein the daily dosage of vitamin K or a derivative thereof is in the range 50μg-1000μg.
8. Use according to any of claims 1 to 7 wherein the medicament or nutritional composition comprises vitamin D or a derivative thereof.
9. Use according to claim 8 wherein said vitamin D is vitamin D3 (cholecalciferol).
10. Use according to any of claims 1 to 9 wherein the medicament or nutritional formulation is for administration to a postmenopausal woman.
11. Use according to any of claims 1 to 10 wherein the medicament or nutritional formulation is to be administered over a period of at least 12 months, preferably at least 36 months.
12. Use according to claim 1 or claim 2 wherein said arteries are the common carotid arteries.
13. A composition for promoting healthy arteries, comprising: (a) vitamin K or a derivative thereof; and
(b) one or more additional components selected from: polyphenols, vitamin C, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty acids, carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B 2; and
(c) optionally, vitamin D or a derivative thereof.
14. A composition according to claim 13 which comprises in a single dose: 0.5-1 mg vitamin K and 5-1 Oμg vitamin D.
15. A composition for promoting healthy arteries which comprises: 0.5- 1.5mg vitamin K; 5-1 Oμg vitamin D; 450-550mg Calcium; 7-12 mg Zinc; and 100-200mg Magnesium.
16. A composition according to claim 15 which comprises about 1 mg
Vitamin K , 8 μg vitamin D3, 500mg Calcium, 10mg Zinc; and 150mg Magnesium.
17. A composition according to any of claims 13 to 16 which is a food or beverage product or a dietary supplement.
18. A kit comprising Vitamin K or a derivative thereof, and optionally vitamin D or a derivative thereof, and a medicament, for simultaneous, separate or sequential administration, wherein said medicament is selected from the group consisting of: anticoagulants, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents, beta-blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics, and calcium antagonists.
19. A method of preventing or treating age-related arterial stiffening, hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke, Monckeberg's sclerosis or coronary heart disease, comprising administering to a person in need of such treatment an effective amount of vitamin K or a derivative thereof and optionally vitamin D or a derivative thereof.
PCT/EP2003/009746 2002-08-30 2003-09-01 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries Ceased WO2004019923A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE60336161T DE60336161D1 (en) 2002-08-30 2003-09-01 COMPOSITIONS WITH VITAMIN K FOR THE PREVENTION OF BLOOD HIGH PRESSURE, LEFT HEART HYPERTROPHY, CONGESTIVE HERZINSUFFICIENCY, MYOCARDINE FARCT, IMPACT AND CORONARY HEART DISEASES BY PREVENTING AGING FROM AGING OF ARTERIES
AU2003264150A AU2003264150A1 (en) 2002-08-30 2003-09-01 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
DK03790959.5T DK1556025T3 (en) 2002-08-30 2003-09-01 Preparations comprising vitamin K for the prevention of hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease by preventing age-related arterial stiffening
AT03790959T ATE499094T1 (en) 2002-08-30 2003-09-01 COMPOSITIONS WITH VITAMIN K FOR THE PREVENTION OF HYPERTENSION, LEFT HEART HYPERTROPHY, CONGESTIVE HEART FAILURE, MYOCARDIAL INFARCTION, STROKE AND CORONARY HEART DISEASE BY PREVENTING AGE-RELATED STIFFENING OF ARTERIES
EP03790959A EP1556025B1 (en) 2002-08-30 2003-09-01 Compositions comprising vitamin k for preventing hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease by preventing age-related stiffening of arteries
US10/525,591 US20060166948A1 (en) 2002-08-30 2003-09-01 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
SI200331997T SI1556025T1 (en) 2002-08-30 2003-09-01 Compositions comprising vitamin k for preventing hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease by preventing age-related stiffening of arteries
US11/144,853 US9364447B2 (en) 2002-08-30 2005-06-03 Compositions for treating or preventing cardiovascular disease
US15/151,970 US12144785B2 (en) 2002-08-30 2016-05-11 Composition of vitamin K and vitamin D for treating or preventing cardiovascular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220182.0A GB0220182D0 (en) 2002-08-30 2002-08-30 Organic compounds
GB0220182.0 2002-08-30

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10525591 A-371-Of-International 2003-09-01
US10/525,591 A-371-Of-International US20060166948A1 (en) 2002-08-30 2003-09-01 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
US11/144,853 Continuation-In-Part US9364447B2 (en) 2002-08-30 2005-06-03 Compositions for treating or preventing cardiovascular disease

Publications (1)

Publication Number Publication Date
WO2004019923A1 true WO2004019923A1 (en) 2004-03-11

Family

ID=9943229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009746 Ceased WO2004019923A1 (en) 2002-08-30 2003-09-01 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries

Country Status (11)

Country Link
US (3) US20060166948A1 (en)
EP (1) EP1556025B1 (en)
AT (1) ATE499094T1 (en)
AU (1) AU2003264150A1 (en)
DE (1) DE60336161D1 (en)
DK (1) DK1556025T3 (en)
ES (1) ES2361740T3 (en)
GB (1) GB0220182D0 (en)
PT (1) PT1556025E (en)
SI (1) SI1556025T1 (en)
WO (1) WO2004019923A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011660A1 (en) * 2003-07-29 2005-02-10 Abbott Laboratories Use of vitamin d to down regulate the renin-angiotensin-aldosterone system
EP1728507A1 (en) * 2005-06-03 2006-12-06 Vitak B.V. Compositions for treating or preventing cardiovascular disease
BE1016566A4 (en) * 2004-05-25 2007-02-06 Psaltopoulos Emmanuel Preparation in the form of pill, tablet, dragee, lozenge or capsule containing calcium, vitamin D and vitamin K to satisfy all human daily requirements e.g. for pregnant and breast feeding women and old people
WO2007046123A3 (en) * 2005-10-21 2007-11-22 Opocrin Spa Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis
FR2916354A1 (en) * 2007-05-25 2008-11-28 Univ Picardie Jules Verne Etab PHARMACEUTICAL COMPOSITION FOR INHIBITING VASCULAR CALCIFICATION.
EP2046312A2 (en) 2006-07-14 2009-04-15 NattoPharma ASA Pharmaceutical and nutraceutical products comprising vitamin k2
US7745494B2 (en) 2005-04-15 2010-06-29 Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
EP2129382A4 (en) * 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR TRANQUILIZATION OF THE CARDIAC MUSCLE
WO2011018501A3 (en) * 2009-08-12 2011-10-20 Laboratoires Expanscience Composition including an unsaponifiable fraction
WO2012080519A1 (en) * 2010-12-17 2012-06-21 Vitak B.V. Use of vitamin k for weight maintenance and weight control
WO2012161572A1 (en) * 2011-05-20 2012-11-29 Friesland Brands B.V. Composition comprising vitamin k2
NL2008294C2 (en) * 2011-05-20 2013-08-19 Friesland Brands Bv Food composition comprising vitamin k and saturated fat.
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
WO2014191466A1 (en) * 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
US9144229B2 (en) 2002-02-01 2015-09-29 Synageva Biopharma Corp. Tissue specific expression of antibodies in chickens
ITPD20140287A1 (en) * 2014-10-30 2016-04-30 Fusaro Maria K-PHARMA
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
US9458236B2 (en) 2001-06-13 2016-10-04 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20180042962A1 (en) * 2016-08-15 2018-02-15 Summit Innovation Labs LLC Vascular Calcification Prevention and Treatment
IT201700085412A1 (en) * 2017-07-26 2019-01-26 Pharmanutra S P A Composition for use in the prevention and treatment of cardiovascular diseases
WO2020185088A1 (en) * 2019-03-11 2020-09-17 Kaydence Pharma As Rapidly improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels by administering vitamin k
EP3773530A4 (en) * 2018-03-30 2022-03-02 Kaydence Pharma AS RAPID IMPROVEMENT OF VASCULAR STATES BY ADMINISTRATION OF VITAMIN K
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
US12246036B2 (en) 2017-08-02 2025-03-11 Pharmanutra S.P.A. Composition for use in the prevention and in the treatment of iron deficiency
WO2025084940A1 (en) * 2023-10-20 2025-04-24 Chde Polska S.A. 2-methyl-3-phytyl-1,4-naphthoquinone for use in the treatment or prevention of diseases with dysfunction of vascular endothelium
US12297406B2 (en) 2019-05-27 2025-05-13 Alesco S.R.L. Method for preparing a composition comprising cetylated fatty acids
US12383525B2 (en) 2019-05-27 2025-08-12 Pharmanutra S.P.A. Compositions comprising cetylated fatty acids and use thereof for the treatment of arthritis and joint inflammatory conditions
EP4674413A1 (en) * 2024-07-01 2026-01-07 Uniwersytet Jagiellonski Synergistic combination of 1-methylnicotinamide (mna) and vitamin k for use in the treatment or prevention of cardiovascular complications of anticancer therapies

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027832A2 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Edta containing compositions and uses thereof
US9642726B2 (en) 2005-07-25 2017-05-09 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9125732B2 (en) 2005-07-25 2015-09-08 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US8923972B2 (en) 2005-07-25 2014-12-30 Vascular Dynamics, Inc. Elliptical element for blood pressure reduction
US9592136B2 (en) 2005-07-25 2017-03-14 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
JP5399072B2 (en) 2005-09-12 2014-01-29 アベラ ファーマスーティカルズ インコーポレイテッド System for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated therewith
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
EP2324838A1 (en) 2005-09-12 2011-05-25 Abela Pharmaceuticals, Inc. Compositions Comprising Dimethyl Sulfoxide (DMSO)
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
US20090053366A1 (en) * 2007-08-21 2009-02-26 Marni Markell Hurwitz Refreshment system having effervescent supplement tablets
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US20100331286A1 (en) * 2008-02-25 2010-12-30 Ray Chow Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function
WO2009108297A2 (en) * 2008-02-25 2009-09-03 Nephrian, Inc. Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function
ES2725524T3 (en) 2008-09-26 2019-09-24 Vascular Dynamics Inc Devices and methods to control blood pressure
BRPI0921494A2 (en) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd method of planning a underground forming sampling operation, method of controlling a underground forming sampling operation, method of controlling a drilling operation for an underground formation, and method of sampling during the drilling operation.
AU2010313253B2 (en) 2009-10-30 2015-02-19 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
US9333228B2 (en) * 2010-06-01 2016-05-10 Top Doctors Labs, Llc Nutritional supplement for recovery, repair, and maintenance
AU2011324792A1 (en) * 2010-11-01 2013-05-30 Viridis Biopharma Pvt. Ltd Dynamic balancing of autonomic nervous system through vitamin MK-7
US8815310B2 (en) * 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
US12612370B2 (en) 2011-03-02 2026-04-28 Thermolife International, Llc Amino acid compositions
HUE032165T2 (en) 2011-04-13 2017-09-28 Thermolife Int Llc N-acetyl beta alanine methods of use
EP2886129A1 (en) * 2013-12-20 2015-06-24 VitaK B.V. Prevention and counteraction of diet-induced thrombosis risk
CN110122866A (en) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis
US20240082198A1 (en) * 2020-10-01 2024-03-14 Emergent Product Development Gaithersburg Inc. Stabilized alkyl nitrite compositions
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
AU2021377897A1 (en) 2020-11-12 2024-09-12 Thermolife International, Llc Methods of increasing blood oxygen saturation
KR20230145103A (en) 2021-02-11 2023-10-17 써모라이프 인터내셔널, 엘엘씨 Method of administering nitric oxide gas
US20230060177A1 (en) * 2021-08-19 2023-03-02 Imam Abdulrahman Bin Faisal University Method for treating athletes subject to pathological cardiac hypertrophy by administering nigella sativa
KR102878403B1 (en) * 2023-01-25 2025-10-28 김성국 Chelation pharmaceutical composition for the treatment of arteriosclerosis and injection method therof using enhanced external counter pulsation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2180747A (en) * 1985-09-20 1987-04-08 Stephen Neil Kreitzman Tryptophan composition for treatment of obesity
EP0613877A1 (en) * 1993-03-01 1994-09-07 Eisai Chemical Co., Ltd. Preparation process of quinone derivative and intermediate for the preparation thereof
EP0679394A2 (en) 1994-04-28 1995-11-02 Eisai Co., Ltd. Menatetronome derivative as antiarteriosclerotic agent
DE19955607A1 (en) * 1999-11-19 2001-06-07 November Ag Molekulare Medizin Drug or coordinated combination of drugs
EP1153548A1 (en) * 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product
WO2003013420A2 (en) * 2001-08-03 2003-02-20 Vitak Bv Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3949098A (en) * 1974-06-05 1976-04-06 Nabisco, Inc. Nutritious orange drink concentrate, process and drink resultant therefrom
US5180747A (en) * 1989-02-28 1993-01-19 Nisshin Flour Milling Co., Ltd. Stabilized fat-soluble vitamin compositions
US5590649A (en) * 1994-04-15 1997-01-07 Vital Insite, Inc. Apparatus and method for measuring an induced perturbation to determine blood pressure
JP3860849B2 (en) * 1994-04-28 2006-12-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-arteriosclerotic agent
GB9600604D0 (en) * 1996-01-12 1996-03-13 Boots Co Plc Composition
GB9713620D0 (en) 1997-06-28 1997-09-03 Boots Co Plc Composition
US6093425A (en) * 1997-11-21 2000-07-25 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
CA2377414A1 (en) * 1999-06-15 2000-12-21 John D. Potter Nutrient formulations for disease reduction, and related treatment and component screening methods
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
SI1728507T1 (en) 2005-06-03 2011-07-29 Nattopharma Asa Use of vitamin K for reversing calcification of blood vessels

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2180747A (en) * 1985-09-20 1987-04-08 Stephen Neil Kreitzman Tryptophan composition for treatment of obesity
EP0613877A1 (en) * 1993-03-01 1994-09-07 Eisai Chemical Co., Ltd. Preparation process of quinone derivative and intermediate for the preparation thereof
EP0679394A2 (en) 1994-04-28 1995-11-02 Eisai Co., Ltd. Menatetronome derivative as antiarteriosclerotic agent
DE19955607A1 (en) * 1999-11-19 2001-06-07 November Ag Molekulare Medizin Drug or coordinated combination of drugs
EP1153548A1 (en) * 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product
WO2003013420A2 (en) * 2001-08-03 2003-02-20 Vitak Bv Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HOEKS AP ET AL., ULTRASOUND MED BIOL, vol. 16, 1990, pages 121 - 8
JPN. J. PHARMACOL., vol. 75, 1997, pages 135 - 143
KAWASHIMA HIDETOSHI ET AL: "Effects of vitamin K2 (Menatetrenone) on atherosclerosis and blood coagulation in hypercholesterolemic rabbits", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 75, no. 2, October 1997 (1997-10-01), pages 135 - 143, XP009020469, ISSN: 0021-5198 *
KOOL MJF ET AL., CARDIOVASCULAR RESEARCH, vol. 28, 1994, pages 610 - 614
M. EDER: "Lehrbuch der Allgemeinen Pathologie und der Pathologischen Anatomie", 1984, SPRINGER VERLAG, HEIDELBERG, XP002260509 *
MH BEERS: "The Merck Manual of Diagnosis and Therapy", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, XP002260508 *
See also references of EP1556025A1
VERMEER C ET AL: "Role of K vitamins in the regulation of tissue calcification.", JOURNAL OF BONE AND MINERAL METABOLISM. JAPAN 2001, vol. 19, no. 4, 2001, pages 201 - 206, XP001153227, ISSN: 0914-8779 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458236B2 (en) 2001-06-13 2016-10-04 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US9144229B2 (en) 2002-02-01 2015-09-29 Synageva Biopharma Corp. Tissue specific expression of antibodies in chickens
WO2005011660A1 (en) * 2003-07-29 2005-02-10 Abbott Laboratories Use of vitamin d to down regulate the renin-angiotensin-aldosterone system
BE1016566A4 (en) * 2004-05-25 2007-02-06 Psaltopoulos Emmanuel Preparation in the form of pill, tablet, dragee, lozenge or capsule containing calcium, vitamin D and vitamin K to satisfy all human daily requirements e.g. for pregnant and breast feeding women and old people
EP2494965A2 (en) 2005-04-15 2012-09-05 The Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy
US7745494B2 (en) 2005-04-15 2010-06-29 Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
EP2305224A2 (en) 2005-04-15 2011-04-06 The Albert Einstein College Of Medicine Of Yeshiva University Vitamin K analog for treatment of skin or mucosal ulceration
US8283382B2 (en) 2005-04-15 2012-10-09 Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
EP1728507A1 (en) * 2005-06-03 2006-12-06 Vitak B.V. Compositions for treating or preventing cardiovascular disease
EP1728507B2 (en) † 2005-06-03 2014-11-12 NattoPharma ASA Use of vitamin k for reversing calcification of blood vessels
WO2007046123A3 (en) * 2005-10-21 2007-11-22 Opocrin Spa Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
NO343923B1 (en) * 2006-07-14 2019-07-08 Pharmaco As Pharmaceutical and nutraceutical products which include at least one compound within the vitamin K2 class and such products for the prevention or therapy of disorders related to bone, cartilage and the cardiovascular system.
EP2046312B1 (en) * 2006-07-14 2020-02-19 Kaydence Pharma AS Pharmaceutical and nutraceutical products comprising vitamin k2
US20100048704A1 (en) * 2006-07-14 2010-02-25 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
EP2046312A2 (en) 2006-07-14 2009-04-15 NattoPharma ASA Pharmaceutical and nutraceutical products comprising vitamin k2
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
EP2129382A4 (en) * 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR TRANQUILIZATION OF THE CARDIAC MUSCLE
FR2916354A1 (en) * 2007-05-25 2008-11-28 Univ Picardie Jules Verne Etab PHARMACEUTICAL COMPOSITION FOR INHIBITING VASCULAR CALCIFICATION.
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US9282759B2 (en) 2009-08-12 2016-03-15 Laboratoires Expanscience Composition including an unsaponifiable fraction
WO2011018501A3 (en) * 2009-08-12 2011-10-20 Laboratoires Expanscience Composition including an unsaponifiable fraction
AU2011343162B2 (en) * 2010-12-17 2016-06-30 Pharmaco As Use of vitamin K for weight maintenance and weight control
US20130267606A1 (en) * 2010-12-17 2013-10-10 Vitak B.V. Use of vitamin k for weight maintenance and weight control
WO2012080519A1 (en) * 2010-12-17 2012-06-21 Vitak B.V. Use of vitamin k for weight maintenance and weight control
NL2008294C2 (en) * 2011-05-20 2013-08-19 Friesland Brands Bv Food composition comprising vitamin k and saturated fat.
CN103687495A (en) * 2011-05-20 2014-03-26 弗里斯兰品牌有限公司 Compositions comprising vitamin K2
RU2606767C2 (en) * 2011-05-20 2017-01-10 Фрисланд Брандз Б.В. Composition containing vitamin k2
WO2012161572A1 (en) * 2011-05-20 2012-11-29 Friesland Brands B.V. Composition comprising vitamin k2
WO2014191466A1 (en) * 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
ITPD20140287A1 (en) * 2014-10-30 2016-04-30 Fusaro Maria K-PHARMA
US20180042962A1 (en) * 2016-08-15 2018-02-15 Summit Innovation Labs LLC Vascular Calcification Prevention and Treatment
CN109641183B (en) * 2016-08-15 2022-07-12 顶峰创新实验室有限公司 Prevention and treatment of vascular calcification and cardiovascular/related diseases
CN109641183A (en) * 2016-08-15 2019-04-16 顶峰创新实验室有限公司 Angiosteosis and the prevention and treatment of angiocarpy/related disease
US11344575B2 (en) 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
IL272138B2 (en) * 2017-07-26 2023-09-01 Pharmanutra S P A Composition for use in the prevention and treatment of pathologies of the cardiovascular apparatus
WO2019021232A1 (en) * 2017-07-26 2019-01-31 Pharmanutra S.P.A. COMPOSITION FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF CARDIOVASCULAR DISORDER DISORDERS
IL272138B1 (en) * 2017-07-26 2023-05-01 Pharmanutra S P A Composition for use in the prevention and treatment of pathologies of the cardiovascular apparatus
IT201700085412A1 (en) * 2017-07-26 2019-01-26 Pharmanutra S P A Composition for use in the prevention and treatment of cardiovascular diseases
US12246036B2 (en) 2017-08-02 2025-03-11 Pharmanutra S.P.A. Composition for use in the prevention and in the treatment of iron deficiency
EP3773530A4 (en) * 2018-03-30 2022-03-02 Kaydence Pharma AS RAPID IMPROVEMENT OF VASCULAR STATES BY ADMINISTRATION OF VITAMIN K
US11911349B2 (en) 2018-03-30 2024-02-27 Nattopharma As Rapidly improving vascular conditions by administering vitamin K
WO2020185088A1 (en) * 2019-03-11 2020-09-17 Kaydence Pharma As Rapidly improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels by administering vitamin k
US12297406B2 (en) 2019-05-27 2025-05-13 Alesco S.R.L. Method for preparing a composition comprising cetylated fatty acids
US12383525B2 (en) 2019-05-27 2025-08-12 Pharmanutra S.P.A. Compositions comprising cetylated fatty acids and use thereof for the treatment of arthritis and joint inflammatory conditions
WO2025084940A1 (en) * 2023-10-20 2025-04-24 Chde Polska S.A. 2-methyl-3-phytyl-1,4-naphthoquinone for use in the treatment or prevention of diseases with dysfunction of vascular endothelium
EP4674413A1 (en) * 2024-07-01 2026-01-07 Uniwersytet Jagiellonski Synergistic combination of 1-methylnicotinamide (mna) and vitamin k for use in the treatment or prevention of cardiovascular complications of anticancer therapies

Also Published As

Publication number Publication date
US20160250160A1 (en) 2016-09-01
EP1556025B1 (en) 2011-02-23
SI1556025T1 (en) 2011-07-29
US9364447B2 (en) 2016-06-14
DK1556025T3 (en) 2011-05-23
US12144785B2 (en) 2024-11-19
EP1556025A1 (en) 2005-07-27
US20050261257A1 (en) 2005-11-24
AU2003264150A1 (en) 2004-03-19
ES2361740T3 (en) 2011-06-21
US20060166948A1 (en) 2006-07-27
DE60336161D1 (en) 2011-04-07
ATE499094T1 (en) 2011-03-15
PT1556025E (en) 2011-05-11
GB0220182D0 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
EP1556025B1 (en) Compositions comprising vitamin k for preventing hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease by preventing age-related stiffening of arteries
US6299896B1 (en) Multi-vitamin and mineral supplement
US7744930B2 (en) Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US5962030A (en) Dietary supplement and method of treatment for diabetic control
US6361800B1 (en) Multi-vitamin and mineral supplement
JP2026062932A (en) Anti-aging agents and methods for preventing aging
EP1728507B2 (en) Use of vitamin k for reversing calcification of blood vessels
US11911349B2 (en) Rapidly improving vascular conditions by administering vitamin K
JPWO2016158212A1 (en) Food composition comprising resveratrol and nicotinamide mononucleotide
JP2001516219A (en) Medical nutrition for diabetics
JPWO2009057775A1 (en) Anti-fatigue agent containing amino acid composition
KR20220154210A (en) Coenzyme Q production promoter and coenzyme Q production promotion method
JP2013028642A (en) Hemodynamic status improving medicine
AU2024264719A1 (en) Rapidly improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels by administering vitamin K
JPWO2007114499A1 (en) Anti-fat accumulation composition
AU2002238931B2 (en) Autonomic controlling agents and health drinks and foods
HU212106B (en) Process for producing pharmaceutical or food compositions containing potassium salts for treating hypertension
JPH05336923A (en) Use of product containing chromium, vitamin e and vitamin c for controlling metabolism of carbohydrate and lipid
JP2007204368A (en) NF-kappaB ACTIVITY INHIBITOR COMPRISING SILK PEPTIDE AS ACTIVE INGREDIENT AND ORAL COMPOSITION
EP3972421A1 (en) Dietary butyrate
Giromini et al. Milk proteins: Their role in cardiovascular health
EP4353089A1 (en) Oral administration agent for pregnant women
JP2024089152A (en) Arterial stiffness increase inhibitor
EP4710775A1 (en) Composition for promoting child development
JP2008266306A (en) Blood cholesterol elevating agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003790959

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006166948

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10525591

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003790959

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10525591

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP